Literature DB >> 9723825

A new regimen for starting warfarin therapy in out-patients.

A Oates1, P R Jackson, C A Austin, K S Channer.   

Abstract

AIMS: Oral anticoagulation is increasingly used in elderly patients with atrial fibrillation to prevent embolic phenomena. The use of anticoagulants in this population is prophylactic rather than therapeutic and so there is no urgency to establish anticoagulation within the desired therapeutic range. The aim of the study was to develop an out-patient regimen for initiation of oral anticoagulation with warfarin which requires only weekly monitoring of the International Normalized Ratio (INR).
METHODS: The study was undertaken in two phases. In the first phase, factors which predict the final maintenance dosage of warfarin were defined and used to build a decision tree and dosage algorithm. In the second study the algorithm was tested. Patients were given 2 mg warfarin daily for 2 weeks and the INR at this time was used to predict the maintenance dose. Patients then attended for weekly measurements of the INR until steady state had been reached. Dosage adjustments were not made unless the INR was >4.0 or <1.5 for 2 consecutive weeks. The accuracy of the prediction was measured by calculating the mean INR of weeks 6-8 and the number of patients in the target range 2.0-3.0 was determined.
RESULTS: One hundred and seven consecutive out-patients (mean age 70 years range 64-86) completed the first study. The age, sex, height, weight, alcohol intake, number of cigarettes smoked, concomitant medication, clinical evidence of right heart failure, liver failure, abnormalities in liver enzyme estimations, baseline INR and INR after 2 weeks of 2 mg warfarin daily were used in a polytomous logistic regression analysis with stepwise inclusion of factors to determine which factors influenced the eventual maintenance dosage of warfarin. The INR after 2 weeks of 2 mg warfarin therapy predicted 70% of the variability of the maintenance dose. Of other factors only the sex of the patient had a large enough effect to be included in the prediction algorithm. One hundred and six patients (mean age 71 years range 50-85 years) completed the second study. Only one patient needed a dose adjustment in the first 2 weeks of warfarin 2 mg daily (INR 4.4). Overall, 60% patients were in the narrow target range (INR 2.0-3.0) at steady state. In five patients the INR was >4.0 at any visit after the second week and needed dosage adjustment. In four patients the INR was <1.5 at steady state.
CONCLUSIONS: We have developed a method of predicting the maintenance dose of warfarin in an elderly population based on the INR after 2 weeks of warfarin 2 mg daily, and the sex of the patient. This is a safe and convenient way of initiating warfarin therapy as an out-patient which requires only weekly INR checks.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723825      PMCID: PMC1873664          DOI: 10.1046/j.1365-2125.1998.00755.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  15 in total

1.  Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy.

Authors:  C S Landefeld; L Goldman
Journal:  Am J Med       Date:  1989-08       Impact factor: 4.965

2.  Aging and the anticoagulant response to warfarin therapy.

Authors:  J H Gurwitz; J Avorn; D Ross-Degnan; I Choodnovskiy; J Ansell
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

3.  Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age.

Authors:  J D Hill; E M Mottram; P D Killeen
Journal:  J R Coll Gen Pract       Date:  1987-04

4.  Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial.

Authors:  B Vadher; D L Patterson; M Leaning
Journal:  BMJ       Date:  1997-04-26

5.  Risk factors for intracranial hemorrhage in outpatients taking warfarin.

Authors:  E M Hylek; D E Singer
Journal:  Ann Intern Med       Date:  1994-06-01       Impact factor: 25.391

6.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

7.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

8.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

9.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11

10.  Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group.

Authors: 
Journal:  Lancet       Date:  1994-02-26       Impact factor: 79.321

View more
  14 in total

1.  Managing atrial fibrillation in elderly people.

Authors:  K M English; K S Channer
Journal:  BMJ       Date:  1999-04-24

2.  Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage.

Authors:  Johanna H H van Geest-Daalderop; Barbara A Hutten; Augueste Sturk; Marcel M Levi
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

3.  Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin.

Authors:  Sameer Ather; Aditi Shendre; T Mark Beasley; Todd Brown; Charles E Hill; Sumanth D Prabhu; Nita A Limdi
Journal:  Am J Cardiol       Date:  2016-05-05       Impact factor: 2.778

Review 4.  Clinical utilization of the international normalized ratio (INR).

Authors:  R S Riley; D Rowe; L M Fisher
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 5.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

6.  Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy.

Authors:  N S Ferder; C S Eby; E Deych; J K Harris; P M Ridker; P E Milligan; S Z Goldhaber; C R King; T Giri; H L McLeod; R J Glynn; B F Gage
Journal:  J Thromb Haemost       Date:  2009-10-30       Impact factor: 5.824

Review 7.  Pharmacogenetics and anticoagulant therapy.

Authors:  Brian F Gage; Charles S Eby
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

Review 8.  Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Authors:  Brian F Gage; Lawrence J Lesko
Journal:  J Thromb Thrombolysis       Date:  2007-10-01       Impact factor: 2.300

Review 9.  Pharmacogenetic testing and therapeutic drug monitoring are complementary tools for optimal individualization of drug therapy.

Authors:  Guillermo Gervasini; Julio Benítez; Juan Antonio Carrillo
Journal:  Eur J Clin Pharmacol       Date:  2010-06-27       Impact factor: 3.064

10.  The health care setting rather than medical speciality impacts on physicians adherence to guideline-conform anticoagulation in outpatients with non-valvular atrial fibrillation: a cross sectional survey.

Authors:  Bernhard Gerber; Georg Stussi; Thomas Rosemann; Oliver Senn
Journal:  BMC Cardiovasc Disord       Date:  2012-02-29       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.